Please login to the form below

Not currently logged in
Email:
Password:

Astellas posts positive bladder therapy data

Astellas has reported positive data from a phase III trial for its overactive bladder therapy candidate mirabegron

Astellas has reported positive data from a phase III trial for its overactive bladder therapy candidate mirabegron.

The data showed that 12 weeks of treatment with mirabegron once-daily led to significant improvements in the number of incontinence episodes, the frequency of urination per 24 hours, and patient-reported outcomes including disease perception, symptom interference and quality of life.

Mirabegron is a selective beta-3 adrenoceptor antagonist designed to facilitate filling of the bladder and storage of urine. A marketing authorisation application for the drug was submitted in Japan in June 2010.

Astellas expects to make regulatory filings in the US and Europe during the second half of 2011.

19th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics